Results 61 to 70 of about 3,389 (131)

Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.

open access: yes, 2017
Objectives: The β-lactamase inhibitor relebactam can restore imipenem activity against imipenem non-susceptible pathogens. Methods: To explore relebactam\u27s safety, tolerability and efficacy, we conducted a randomized (1:1:1), controlled, Phase 2 trial
Sims, Matthew
core  

Clinical imipenem non-susceptible Klebsiella pneumoniae isolates from China: Epidemiology, molecular characterization and in vitro activity of imipenem/relebactam

open access: yes
Objective: To describe the epidemiological and molecular characterization and in vitro activity of imipenem/relebactam against imipenem non-susceptible (IPMNS) Klebsiella pneumoniae isolates in China. Methods: K.
Xiaobing Chu   +11 more
core   +1 more source

In Vitro Activity of Imipenem-Funobactam Against Clinical Isolates of Gram-Negative Bacilli. [PDF]

open access: yesAntibiotics (Basel)
Karlowsky JA   +5 more
europepmc   +1 more source

Addressing therapeutic options for KPC-3-producing ST307-<i>Klebsiella pneumoniae</i>: insights from <i>in vitro</i> evolution and mutant prevention strategies. [PDF]

open access: yesAntimicrob Agents Chemother
Hernández-García M   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy